Developing novel biological drugs for complex chronic diseases
Targeting TGF-β for fibrosis and cancer.
Newly discovered
Novel soluble splice variant of human TGF-β type II receptor fused to antibody Fc domain
Binds TGF-β1, β2, & β3
Unique 13 amino acid stretch allows the binding to the three isoforms of TGF-β, to maximize its potential application on several indications
Decoy receptor
Our biomolecule neutralizes excessive TGF-β levels observed in several conditions
About us
Overview
RADBIO is a biotech company founded in 2018 by experienced scientists and entrepreneurs, designing and developing a novel biomolecule that neutralizes TGF-β, as a therapeutic for fibrotic diseases and solid tumors with unmet medical needs.
Strategy
TGF-β is a well validated target known as the “master regulator of fibrosis”. We aim at harnessing the potential application of our biomolecule in several indications where TGF-β isoforms are upregulated.
INDICATION
DISCOVERY & CHARACTERIZATION
PROOF OF CONCEPT STUDIES
PRECLINICAL CMC / GLP-TOX
CLINICAL PHASES
BRECEPT
Inhibitor of TGF-β signaling pathway
- SYSTEMIC SCLEROSIS
- LIVER FIBROSIS & NASH
- WOUND HEALING
- COLORECTAL CANCER
- BREAST CANCER
